The first major breakthrough in AD drug development was the finding that basal forebrain cholinergic neurons degenerate early in the disease.[15–17] Since the cholinergic system was found to be important for memory in several models, this finding led to the development of acetylcholinesterase inhibitors (AChEIs) for the treatment of AD. Here, ACHE is linked to Alzheimer disease.